跳至主要内容
临床试验/NCT00382460
NCT00382460已完成4 期

Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)

Bristol-Myers Squibb0 个研究点目标入组 4,000 人开始时间: 2000年11月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
4,000
主要终点
To demonstrate the clinical equivalence of pravastatin 40 mg and atorvastatin 80 mg in reducing death or major cardiovascular event after 2 years

研究概览

简要总结

The primary purpose of the study was to evaluate 4000 subjects with acute coronary syndrome by comparing pravastatin 40 mg to atorvastatin 80 mg to determine if they are clinically equivalent, and to evaluate the effectiveness of gatifloxacin therapy in reducing cardiovascular events in combination with statin therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Prevention
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Hospitalization for MI or high risk unstable angina within the last 10 days.
  • Total cholesterol 240 mg/dl or greater.
  • Stabilized post ACS

排除标准

  • Co-morbidity with life expectations no more than 2 years.
  • Current lipid lowering therapy
  • Corrected QT interval
  • Need for Class IA or III antiarrhythmic agent

结局指标

主要结局

To demonstrate the clinical equivalence of pravastatin 40 mg and atorvastatin 80 mg in reducing death or major cardiovascular event after 2 years

To demonstrate in subjects with ACS that Gatifloxacin is effective in reducing death or major cardiovascular event after 2 years, compared to placebo.

次要结局

  • To compare the risk of nonfatal MI or coronary heart disease death between pravastatin and atorvastatin, and gatifloxacin and placebo.

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry

相似试验

Pravastatin or Atorvastatin Evaluation and Infection... | 临床试验